A5086361192- PARP inhibition in cancer therapy
- Ovarian cancer diagnosis and treatment
- Chronic Lymphocytic Leukemia Research
- Liver physiology and pathology
- Chronic Myeloid Leukemia Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Monoclonal and Polyclonal Antibodies Research
- Quinazolinone synthesis and applications
- Lymphoma Diagnosis and Treatment
- DNA Repair Mechanisms
- Musculoskeletal pain and rehabilitation
- Pain Mechanisms and Treatments
- BRCA gene mutations in cancer
- Pain Management and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Neutropenia and Cancer Infections
- Diagnosis and treatment of tuberculosis
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Integrated Circuits and Semiconductor Failure Analysis
- Neonatal Respiratory Health Research
- HER2/EGFR in Cancer Research
- Acute Myeloid Leukemia Research
NIMS University
2023
Epizyme (United States)
2019-2022
Palmetto Hematology Oncology
2019
Tesaro (United States)
2014-2018
AVEO Oncology (United States)
2012-2018
Copenhagen University Hospital
2017
All India Institute of Medical Sciences Bhopal
2017
All India Institute of Medical Sciences Raipur
2017
All India Institute of Medical Sciences
2016-2017
Curis (United States)
2017
Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate the efficacy of niraparib versus placebo as maintenance treatment for platinum-sensitive, recurrent cancer.In this randomized, double-blind, phase 3 trial, were categorized according presence or absence a germline BRCA mutation (gBRCA cohort and non-gBRCA cohort) type randomly assigned 2:1 ratio receive (300 mg)...
Summary Background There is a limited range of treatments for severe atopic dermatitis (AD). Azathioprine has often been used but there no randomized controlled trial this drug to confirm its efficacy in AD. Objectives To establish or refute the azathioprine investigate safety and tolerability patient population. Methods We performed double‐blind, randomized, placebo‐controlled, crossover adult patients with Each treatment period was 3 months' duration. Treatments were 2·5 mg kg−1 day−1...
(Abstracted from N Engl J Med 2016;375(22):2154–2164) The initial response rate to platinum and taxane treatment in patients with advanced ovarian cancer is high. However, the effectiveness of this regimen diminishes over time, most relapse; retreatment, relapses occur at shorter intervals until patient death.
Background Stump and phantom pains are debilitating sequelae of amputations that often resistant to treatment. The efficacy pharmacologic therapies, including opioids sodium channel blockers, for postamputation pain is uncertain. Methods authors conducted a double-blind, randomized, placebo-controlled, crossover study in adult patients with 6 months or longer greater than 3 on 0-10 numeric rating scale. Each the three treatment periods (morphine, mexiletine, placebo) included 1-week...
Bosutinib, a potent ATP-competitive, quinolinecarbonitrile Src/Abl kinase inhibitor, was tested in this first-in-human phase I trial patients with advanced solid tumor malignancies.This conducted 2 parts. In part 1 (dose escalation), increasing oral bosutinib doses were administered using 3 + design. expansion), approximately 30 each refractory colorectal, pancreas, or non-small cell lung cancer treated at the recommended II dose (RP2D). Primary efficacy endpoints for median progression-free...
<h3>Background and Objectives:</h3> Complex regional pain syndrome (CRPS) is a poorly understood disorder with little information on the natural course of disease. Changes in its diagnostic criteria have simplified identification this syndrome, but convincing epidemiological data regarding are still lacking. Here, we collected other relevant CRPS via Web-based survey to develop better understanding epidemiology, symptoms, progression, therapy, associated psychosocial factors related CRPS....
BackgroundThe combination of atezolizumab, a monoclonal antibody that targets programmed death-ligand 1 (PD-L1) and inhibits the interaction between PD-L1 its receptors, tazemetostat, an EZH2 inhibitor, may lead to selective epigenetic reprogramming, alter tumor microenvironment, provide additive or synergistic response patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).Materials MethodsThis was open-label, phase Ib study assessing safety, tolerability, preliminary...
TPS3099 Background: Programmed-death 1 (PD-1) and V-domain Ig suppressor of T-cell activation (VISTA) are independent immune checkpoints that negatively regulate function implicated in various malignancies. Preclinical studies have demonstrated dual blockade these pathways is synergistic. CA-170 a first-in-class oral small molecule directly targets both PD-1/PD-L1 VISTA has shown anti-tumor activity multiple preclinical models. Methods: The dose escalation phase target enrollment 50 pts with...
This study evaluated the safety, tolerability, pharmacodynamics, pharmacokinetics, and antitumor activity of ficlatuzumab, a humanized hepatocyte growth factor (HGF) inhibitory monoclonal antibody, as monotherapy in patients with advanced solid tumors liver metastases.Patients p-Met (phosphorylated c-Met)-positive enrolled three dose-escalation cohorts, receiving ficlatuzumab 2, 10, or 20 mg/kg once per 14-day cycle. Pharmacodynamic changes tumor biopsies serum, clinical were assessed.No...
Niraparib is an investigational oral, once daily, selective poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor. In the pivotal Phase 3 NOVA/ENGOT/OV16 study, niraparib met its primary endpoint of improving progression-free survival (PFS) for adult patients with recurrent, platinum sensitive, ovarian, fallopian tube, or peritoneal cancer in complete partial response to platinum-based chemotherapy. Significant improvements PFS were seen all patient cohorts regardless biomarker status....
Objective. The efficacy of transdermal fentanyl in chronic neuropathic pain has not been well studied. We examined the effects on and function patients with states. Design. A 16-week open-label study evaluated pre- postdrug therapy effects. An actigraph was used to record scores (0–10) three times a day activity level (8 am−8 pm) continuously. Pain were also entered diary logs. Setting. conducted subjects visiting Johns Hopkins Hospital as outpatients. Patients. Patients peripheral (N = 25),...
<h3>Background</h3> Approximately 1/3 of RA patients (pts) on biologics receive them as monotherapy (without other DMARDs) [1,2]. TCZ, an inhibitor IL-6 receptor signalling, has been studied in 3 clinical trials [3–5], but direct comparison with anti-TNF agent not previously performed. <h3>Objectives</h3> To evaluate efficacy and safety TCZ vs the ADA, both given monotherapy, pts DAS28 >5.1. <h3>Methods</h3> ADACTA was a multicentre, randomised, double-blind, 24-wk study designed...
Abstract Hepatocyte growth factor (HGF)/c‐Met pathway dysregulation is a mechanism for epidermal receptor (EGFR) tyrosine kinase inhibitors (TKIs). Ficlatuzumab (AV‐299; SCH 900105), humanized IgG 1 κ HGF inhibitory monoclonal antibody, prevents HGF/c‐Met ligand–mediated activation. This phase 1b study assessed the safety/tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of ficlatuzumab plus gefitinib in Asian patients with previously treated advanced non–small cell...
Niraparib is a highly selective inhibitor of PARP-1 and PARP-2 approved in the United States for maintenance treatment adult patients with recurrent ovarian cancer complete or partial response to platinum-based chemotherapy. In this open-label crossover study, we evaluated effects food on niraparib pharmacokinetics (PK) safety. Patients received single 300-mg dose either after high-fat meal under fasting conditions. After 7-day PK assessment, all second opposite condition, followed by...
Background More than 50% of amputees report experiencing significant stump or phantom pain. Stump pain is often attributed to the formation a neuroma at amputation site. Experimental evidence shows that catecholamines and α-adrenoceptors play role in mechanisms associated with neuromas. We investigated whether administration physiological doses norepinephrine (NE) distal region probable evoked if local phentolamine attenuated NE-evoked patients postamputation Methods Twenty participated...